NCT03340129 2026-02-02
ABC-X
Melanoma Institute Australia
Phase 2 Recruiting
Clinical Trials
29 trialsNCT02648997 2026-01-26
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03873818 2026-01-09
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02374242 2025-12-10
ABC
Melanoma Institute Australia
Phase 2 Active not recruiting
NCT03233152 2025-11-21
GlitIpNi
Universitair Ziekenhuis Brussel
Phase 1/2 Active not recruiting
NCT02939300 2025-11-14
Ipilimumab and Nivolumab in Leptomeningeal Metastases
Massachusetts General Hospital
Phase 2 Completed
NCT02696993 2025-11-10
Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT05704933 2025-10-20
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Completed
NCT06712927 2025-09-08
Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
Stanford University
Phase 2 Recruiting
NCT07134842 2025-08-21
WinGlio-ipi
University College, London
Phase 1 Recruiting
NCT05341349 2025-07-30
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Emory University
Phase 1 Active not recruiting
NCT04003649 2025-07-10
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
City of Hope Medical Center
Phase 1 Recruiting
NCT01703507 2025-05-16
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
Thomas Jefferson University
Phase 1 Completed
NCT05012254 2025-04-09
NIVIPI-Brain
FundaciĆ³n GECP
Phase 2 Active not recruiting
NCT04239040 2025-03-19
GVAX Plus Checkpoint Blockade in Neuroblastoma
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT05302921 2025-01-01
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Children's National Research Institute
Phase 2 Completed
NCT03458455 2023-11-01
TREATMENT
Oslo University Hospital
Unknown
NCT03563729 2023-07-13
MEMBRAINS
Herlev Hospital
Phase 2 Recruiting
NCT03430791 2023-02-02
Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
Baptist Health South Florida
Phase 2 Terminated
NCT02829931 2023-01-19
Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02115139 2022-11-08
GRAY-B
Grupo EspaƱol Multidisciplinar de Melanoma
Phase 2 Completed
NCT04434560 2022-07-26
Neoadjuvant Immunotherapy in Brain Metastases
Duke University
Phase 2 Terminated
NCT03422094 2021-10-27
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Washington University School of Medicine
Phase 1 Terminated
NCT02097732 2021-05-12
Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT03707457 2020-07-02
Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT03460782 2019-11-08
An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas
Center Trials & Treatment
No longer available
NCT03297463 2018-08-01
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
Masonic Cancer Center, University of Minnesota
Phase 1/2 Withdrawn
NCT02662725 2016-01-25
IPI+RTS
University Hospital, Lille
Phase 2 Completed
NCT02460068 2015-06-02
NIBIT-M2
Italian Network for Tumor Biotherapy Foundation
Phase 3 Unknown